Bio Balance

What Bio Balance does

Bio Balance, Inc. is a privately held New York biotechnology/pharmaceutical discovery company founded in 1993 by Richard Lanzara, Ph.D., who continues to lead it as President and Principal Scientific Officer. The company is built around a proprietary two-state biophysical model that describes G protein-coupled receptor (GPCR) activation via cysteine/sulfhydryl modulation and acid-base chemistry, and around a derived methodology called Optimal Ratio Combinations (ORCs), in which specific agonist-to-antagonist ratios are calculated to prevent drug-receptor desensitization (down-regulation, tolerance, and fade). This IP is protected by three issued US patents (USP 5,597,699; 6,593,094; 6,673,558) and has been validated in published in vivo animal studies for agents including dobutamine, isoproterenol, L-dopa, and morphine combinations.

The company's commercial offering is essentially its intellectual property and computational expertise: it licenses the ORC technology to pharmaceutical companies seeking to improve existing drugs or develop combination therapies, and it conducts collaborative research with academic and industry partners, supported by molecular modeling, 3D pharmacophore construction, electrostatic potential calculation, and a downloadable prototype software tool that fits dose-response data to the two-state model. Supporting partnerships include a long-running co-development with Dr. Lester Rubenstein at Mount Sinai School of Medicine and contract research performed by Gwathmey, Inc. The customer base is described as horizontal across pharmaceutical companies and academic research institutions, though no commercial licensing customers are named in the available data.

The business model is asset-light and licensing-oriented: revenue (if any) is expected to come from case-by-case negotiated licensing royalties and collaborative research agreements rather than product sales. The company operates with 1-10 employees from a single headquarters in New York, has not disclosed institutional funding or revenue, and has not announced commercial-scale product launches beyond the 2006 prototype software. Distribution is framed as global via direct licensing, although US incorporation and operations are the only geography confirmed in the data.

Name

Bio Balance

Legal name

Bio Balance, Inc.

Website

https://bio-balance.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

1–10 employees

Short description

Bio Balance is a privately held New York biotechnology discovery company founded in 1993 that develops a patented two-state biophysical model and Optimal Ratio Combination technology to prevent drug-receptor desensitization, licensing it to pharmaceutical companies and academic researchers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Discovery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAJAE

Cheminformatics & Molecular Modeling / CADD

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAFAM

In Silico / Computational Toxicology & PK/PD Modeling

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

SECONDARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Drug discovery technology
• Receptor desensitization
• Biopharmaceutical licensing
• Molecular modeling services
• GPCR research

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Licensing of patented technology for preventing drug-receptor desensitization to pharmaceutical companies. The company has patents for compositions to enhance drug safety and efficacy, and methods for determining drug combinations.
2. Collaborative Research Agreements: Mutually beneficial collaborations with industry, academia, and research organizations for co-development of enhanced pharmaceuticals using their proprietary receptor models.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Bio Balance develops and licenses a proprietary two-state biophysical receptor model and Optimal Ratio Combinations (ORCs) technology that combines agonist and antagonist drugs in mathematically-calculated ratios to prevent GPCR receptor desensitization, sustain therapeutic response, and reduce side effects. The company also offers prototype dose-response analysis software and 3D molecular modeling services, targeting pharmaceutical companies and academic researchers developing enhanced therapeutics for conditions such as heart failure, asthma, Parkinson's Disease, and pain.

Product overview

Bio Balance is a biotechnology/pharmaceutical discovery company that offers a portfolio of products centered on its proprietary two-state biophysical receptor model and Enhanced Pharmaceuticals technology (Optimal Ratio Combinations/ORCs). The core offering combines agonist and antagonist drugs in mathematically-calculated ratios to prevent receptor desensitization. Supporting products include a downloadable prototype program for dose-response data analysis and molecular modeling services for receptor research. The company licenses its technology for drug development applications targeting conditions such as heart failure, asthma, Parkinson's disease, and pain management.

Differentiator

Problem solved

Functional benefit

Products and services

• Optimal Ratio Combinations (ORCs) Technology Proprietary technology combining agonist and antagonist drugs in mathematically-calculated optimal ratios to prevent GPCR receptor desensitization (tachyphylaxis, tolerance, fade, down-regulation), sustaining therapeutic response and reducing side effects compared to single-molecule drugs. Licensed to pharmaceutical companies for indications including heart failure, asthma, Parkinson's Disease, and pain management.
• Prototype Download Program Downloadable software prototype that calculates high and low affinities for Bio Balance's two-state biophysical model for the initial receptor response, designed to assist researchers with analysis of dose-response data displaying desensitization or down-regulation.
• Molecular Modeling and Graphics Service Construction of 3D models of bioactive molecules with electronic properties, electrostatic potential plots, and protein modeling for receptor recognition and activation studies; supports design of bioactive agents and assessment of their adverse effects via explicit modeling with target proteins.
• Two-State Biophysical Receptor Model Biophysical model describing receptor activation through cysteine modulation and acid-base mechanisms, relating the response to a fundamental equation for physical equilibrium. Demonstrates that receptors function as poised chemical balances shifted by unequal ligand binding, with efficacy determined by ligand preference for base over acid forms of the receptor.

Quantifiable outcome

• Isoproterenol/metoprolol combination (1:85 ratio) sustained dP/dt response at 96% vs. -15% for agonist alone at 10 μg/kg/min infusion in rat studies
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Gwathmey, Inc.coreImplementation/ SI/ Consulting PartnerContract research organization (CRO) that performed all animal experiments for Bio Balance's receptor desensitization studies. Located in Cambridge, MA. Conducted in vivo testing of isoproterenol/metoprolol and dobutamine/metoprolol combinations in rat models.
• CEREPsupportingTechnology or IntegrationDrug screening and contract research company providing pharmacological profiling services. Listed as a collaborator for receptor research activities.
• DSS Infotech InternationalsupportingTechnology or IntegrationSoftware development partner that collaborated with Bio Balance to develop a prototype program for calculating high and low affinities for the two-state biophysical receptor model. The prototype assists researchers with dose-response data analysis.
• Dr. Lester Rubenstein, Mount Sinai School of MedicinecoreStrategic or Co-development PartnerEight-year collaboration with Dr. Lester Rubenstein at Mount Sinai's Department of Physiology and Biophysics to derive the two-state acid-base model and corresponding molecular model for cysteine modulation of ligand binding. Co-author of key publications on GPCR activation.
• Dr. Peter Cherry, CCNYsupportingStrategic or Co-development PartnerAcademic collaborator at the City College of New York participating in molecular pharmacology and receptor research partnerships.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Recursion Pharmaceuticals: Recursion operates a broader AI-driven drug discovery platform combining computation with high-throughput biology to generate novel therapeutic candidates. While its scale and modality breadth are much greater than Bio Balance's, both center proprietary computational science as a licensable platform for pharma partnerships.
• Alkermes: Alkermes is a CNS-focused specialty pharma built around proprietary long-acting injectable and oral controlled-release formulations that address receptor-tolerance and adherence challenges, the same underlying pharmacology Bio Balance addresses with ORC antagonist combinations. Both work at the intersection of receptor pharmacology and drug reformulation, though Alkermes operates as a commercial manufacturer rather than a licensor.
• Nektar Therapeutics: Nektar develops polymer-conjugated and engineered small molecules designed to improve tolerability, reduce receptor-mediated side effects, and enable less frequent dosing - conceptually adjacent to Bio Balance's mission of preventing receptor desensitization. Both pursue reformulation / engineering of existing molecules to solve receptor response issues for pharma partners.
• Dassault Systèmes BIOVIA: BIOVIA (formerly Accelrys/Molecular Simulations) is the broad-incumbent suite of molecular modeling, cheminformatics, and protein modeling tools used across pharma R&D. Bio Balance's 3D molecular modeling and electrostatic potential work targets the same receptor-design workflow BIOVIA occupies at much larger scale and broader feature breadth.

Direct peers

• OpenEye Scientific (Cadence): OpenEye builds cheminformatics and molecular modeling software (including OMEGA, ROCS, and FRED) for drug discovery, directly comparable to Bio Balance's molecular modeling and electrostatic potential services for GPCRs. Both sell computational receptor-ligand modeling tools into pharma discovery workflows.
• Certara: Certara provides modeling and simulation software (including Phoenix WinNonlin for PK/PD and Quantitative Systems Pharmacology) used by pharma to predict in vivo response - the same translational slice Bio Balance targets with its desensitization PK/PD and receptor-response models. Both companies monetize proprietary computational science into pharma licensing and collaboration revenue.
• Simulations Plus: Simulations Plus builds physiologically-based pharmacokinetic (PBPK) and quantitative modeling software (GastroPlus, MonolixSuite) that predicts drug behavior in vivo, sharing Bio Balance's positioning of mathematics-driven receptor and PK models for pharma development. Both target similar enterprise pharma buyers with computational models rather than wet-lab assets.
• Schrödinger, Inc. Schrödinger is a computational chemistry and molecular modeling platform company whose physics-based and machine-learning tools are used to design and optimize drug candidates, directly analogous to Bio Balance's two-state biophysical model and 3D molecular modeling of GPCR ligand interactions. Both companies build IP-anchored receptor modeling technology sold or licensed to pharma R&D organizations.

Emerging players

• Insitro: Insitro combines machine learning with high-throughput biology to discover and optimize therapeutics across multiple indications, monetizing a proprietary platform into pharma collaborations. Bio Balance's narrower ORC platform addresses a specific pharmacological mechanism within a similar platform-licensing business model.
• Atomwise: Atomwise applies deep learning to small-molecule design against protein targets, including GPCRs, pursuing pharma partnerships for novel hits. Bio Balance tackles a narrower receptor-response problem with physics-based modeling rather than deep learning, but both sell proprietary target-to-molecule design technology into pharma pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bio1balance
• Facebookfacebook.com/Bio1Balance
• LinkedInlinkedin.com/company/bio1balance

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio Balance